A Phase 3 interventional study of gabapentin in Epilepsies, Partial, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 26 sites in Japan. Open to participants aged 3 Years to 15 Years. Per ClinicalTrials.gov, last updated 2021-02-03.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Epilepsies, Partial by Viatris Inc. — none open to participants now, none under way, none of them phase 3. Epilepsies, Partial · Viatris Inc..
Among the 15 studies in Epilepsies, Partial by Viatris Inc., this one is the 9th largest by enrollment of the 13 interventional ones that give a count, is one of 4 that started in 2008, is one of 8 in phase 3, and was the 11th registered.
243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.
Browse Epilepsies, Partial studies →None of the 15 studies in Epilepsies, Partial by Viatris Inc. is open now. The open studies under Epilepsies, Partial, anywhere →
Of the 37 Epilepsies, Partial studies recruiting now, 9 (24%) set no upper age limit and 24 (65%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.
This study: 3 Years to 15 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 4 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 92 is close to the median of 90 across 187 interventional studies indexed under Epilepsies, Partial.
Median enrollment 136 across the 13 interventional studies, 678 across the 2 observational. Of the 15 that completed or were terminated, 15 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Epilepsies, Partial by Viatris Inc., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Examine the efficacy, safety and pharmacokinetics of gabapentin as adjunctive therapy in Japanese pediatric patients with partial seizures
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: gabapentin
Orally administered gabapentin
Response Ratio of Gabapentin in Japanese Pediatric Patients With Partial Seizures
The Response Ratio calculated by the following equation was assessed as the primary endpoint: R Ratio = (T-B) / (T+B) where T is seizure frequency per 28 days (i.e., the number of seizures per 28 days) calculated from the total number of seizures for the 12-week treatment period, and B is seizure frequency per 28 days (i.e., the number of seizures per 28 days) calculated from the total number of seizures for the 6-week baseline period.
Time frame: 12 weeks
Responder Rate
Responder Rate was defined as the percentage of subjects with a 50% or greater reduction in the seizure frequency per 28 days for the 12-week treatment period in comparison with the frequency per 28 days for the 6-week baseline period.
Time frame: 12 weeks
Percent Change in Seizure Frequency (PCH)
PCH calculated by the following equation was assessed as secondary endpoint: PCH = 100 (T-B) / B where T is seizure frequency per 28 days (i.e., the number of seizures per 28 days) calculated from the total number of seizures for the 12-week treatment period, and B is seizure frequency per 28 days (i.e., the number of seizures per 28 days) calculated from the total number of seizures for the 6-week baseline period.
Time frame: 12 weeks
Participants were screened at 27 centers in Japan.
| Milestone | Gabapentin |
|---|---|
| Started | 89 |
| Completed | 80 |
| Not completed | 9 |
| Withdrew: Adverse event | 4 |
| Withdrew: Lack of efficacy | 4 |
| Withdrew: Protocol violation | 1 |
The Response Ratio calculated by the following equation was assessed as the primary endpoint: R Ratio = (T-B) / (T+B) where T is seizure frequency per 28 days (i.e., the number of seizures per 28 days) calculated from the total number of seizures for the 12-week treatment period, and B is seizure frequency per 28 days (i.e., the number of seizures per 28 days) calculated from the total number of seizures for the 6-week baseline period.
| ratio | Gabapentin |
|---|---|
| Response Ratio of Gabapentin in Japanese Pediatric Patients With Partial Seizures | -0.158 (-0.221 to -0.096) |
Responder Rate was defined as the percentage of subjects with a 50% or greater reduction in the seizure frequency per 28 days for the 12-week treatment period in comparison with the frequency per 28 days for the 6-week baseline period.
| Percentage of Subjects | Gabapentin |
|---|---|
| Responder Rate | 19.8 (12.0 to 29.8) |
PCH calculated by the following equation was assessed as secondary endpoint: PCH = 100 (T-B) / B where T is seizure frequency per 28 days (i.e., the number of seizures per 28 days) calculated from the total number of seizures for the 12-week treatment period, and B is seizure frequency per 28 days (i.e., the number of seizures per 28 days) calculated from the total number of seizures for the 6-week baseline period.
| Percent Change | Gabapentin |
|---|---|
| Percent Change in Seizure Frequency (PCH) | -24.4 (-100.0 to 192.9) |
Collected over 12-week treatment period, and 1-week follow-up period. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Gabapentin | — | 1/89 (1.1%) | 73/89 (82%) |
| Event | Gabapentin |
|---|---|
| PharyngitisInfections and infestations | 1/89 |
| Event | Gabapentin |
|---|---|
| SomnolenceNervous system disorders | 35/89 |
| NasopharyngitisInfections and infestations | 24/89 |
| InfluenzaInfections and infestations | 9/89 |
| FallInjury, poisoning and procedural complications | 7/89 |
| DiarrhoeaGastrointestinal disorders | 6/89 |
| PharyngitisInfections and infestations | 6/89 |
| ContusionInjury, poisoning and procedural complications | 6/89 |
| PyrexiaGeneral disorders | 5/89 |
| RashSkin and subcutaneous tissue disorders | 5/89 |
| Upper respiratory tract infectionInfections and infestations | 4/89 |
| Age, Customized(Subjects) | Gabapentin |
|---|---|
| >= 3 years and < 5 years | 11 |
| >= 5 years and < 13 years | 63 |
| >= 13 years and =< 15 years | 15 |
| Sex: Female, Male(Participants) | Gabapentin |
|---|---|
| Female | 40 |
| Male | 49 |
The record gives a start of Jan 2008, a primary completion of Dec 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2011, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gabapentin
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →